Can the vaginal contraceptive ring (NuvaRing) cause recurrent vulvovaginal candidiasis?

Can the Birth Control Ring Cause Recurrent Yeast Infections?

The vaginal contraceptive ring (NuvaRing) does not directly cause recurrent yeast infections and may actually promote a healthier vaginal environment by supporting lactobacilli-dominated flora, though individual susceptibility varies and women with pre-existing vestibulodynia or recurrent vulvovaginitis require closer monitoring.

Evidence on the Ring and Vaginal Environment

The relationship between NuvaRing and yeast infections is more nuanced than a simple cause-and-effect:

Protective effects observed:

• A randomized study in Rwanda demonstrated that NuvaRing promoted lactobacilli-dominated vaginal communities even in a population with 48% baseline bacterial vaginosis prevalence 1
• Mean Nugent scores decreased significantly with ring use, and Lactobacillus species increased while pathogenic bacteria decreased 1
• A longitudinal study using 16S rRNA sequencing found no adverse changes in vaginal microbiome composition after 2 months of CVR use, with Lactobacillus crispatus remaining the dominant strain 2

Potential concerns:

• Laboratory studies confirm that Candida species can adhere to the ring material, which could theoretically facilitate VVC development in susceptible patients 3
• One comparative study found intrauterine device users (including LNG-IUS) had increased vaginal Candida colonization compared to other contraceptive methods, though this was not specific to vaginal rings 4
• In the longitudinal microbiome study, one woman with a history of vestibulodynia and recurrent vulvovaginitis showed increased bacterial biodiversity and anaerobic bacteria during ring use 2

FDA Label Information

The NuvaRing FDA label does not list vulvovaginal candidiasis as a contraindication or specific adverse effect related to ring use 5. The label notes that NuvaRing may not be suitable for women with conditions making the vagina more susceptible to irritation or ulceration, and rare cases of vaginal/cervical erosion have been reported 5.

Clinical Approach

For women considering NuvaRing:

• The ring is appropriate for most women and does not increase VVC risk in the general population
• Combined hormonal contraception (including CVR) may actually reduce dysbiosis risk compared to non-hormonal methods

High-risk populations requiring caution:

• Women with documented recurrent VVC (≥3 episodes per year) 6
• Those with history of vestibulodynia combined with recurrent vulvovaginitis 2
• Women with current active VVC should be treated before ring insertion

If VVC develops during ring use:

• Treat the acute infection with standard azole therapy per CDC guidelines 6
• The ring does not need to be removed during treatment unless specifically advised
• If infections recur (≥3 episodes in 12 months), consider alternative contraception, particularly progesterone-only pills which showed lower Candida carriage rates in one study 4

Common Pitfalls to Avoid

1. Don't assume the ring causes VVC - The evidence suggests neutral to beneficial effects on vaginal flora in most women
2. Don't overlook biomass accumulation - While bacteria adhere to the ring surface, this mirrors the vaginal microbiota and doesn't appear clinically significant 1
3. Don't ignore individual susceptibility - Women with pre-existing recurrent infections need individualized assessment 2

The recurrence rate of VVC in general populations is 17 per 100 person-years, with sexual practices and partner factors playing more significant roles than contraceptive choice 7. The ring itself is not a primary driver of recurrent yeast infections for most users.